11/18
08:07 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
11/4
08:19 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
11/4
08:19 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
11/4
05:01 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
11/4
05:01 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
10/4
08:06 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
9/27
10:00 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
9/27
10:00 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
9/27
07:49 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $23.00 price target on the stock, up previously from $19.00.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $23.00 price target on the stock, up previously from $19.00.
9/25
09:21 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
9/9
11:23 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
9/9
11:23 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
9/9
10:11 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
9/3
08:04 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.